UNSPSC 51111647: Nolatrexed

This classification denotes a thymidylate synthase inhibitor and folate antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K75ZUN743Q. European Medicines Agency schedules Nolatrexed in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09342MIG. Nolatrexed generally arises in the molecular formula C14H12N4OS.

The term NOLATREXED is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 no. 2 1999, list 40.) NOLATREXED is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nolatrexed under HS 29335995 and SITC 51576. As of Q4 2014, NOLATREXED remains the US FDA Preferred Term for this commodity. SMILES: S(C1C2C([NH]C(NC2=O)N)CCC1C)C1CCNCC1.

UNSPSC 51111647 Nolatrexed is a Commodity code covering a specific pharmaceutical agent used in oncology treatment. State and local procurement activity under this code is minimal to nonexistent in the available recent-opportunities record. The code itself names a single chemotherapy drug rather than a broad service or product family, and state and local governments do not typically procure individual pharmaceutical agents through open competitive solicitations tagged to specific drug names. When public bodies acquire oncology pharmaceuticals, they do so through group purchasing organizations, state pharmaceutical contracts, or health system formularies rather than discrete RFPs or RFQs keyed to a single active ingredient.

No recent state or local contract opportunities appear in the source record under this code. Business development professionals evaluating procurement activity in pharmaceutical supply should focus on higher-tier UNSPSC families covering drug purchasing as a whole, state health department cooperative-purchasing vehicles, or prime-contractor relationships with established pharmaceutical distributors serving public health systems and correctional facilities, rather than watch for discrete solicitations under single-drug commodity codes.